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Abstract The plasma proteins of the complement system
are essential in the innate immune response against
bacteria. Complement labels bacteria with opsonins to
support phagocytosis and generates chemoattractants to
attract phagocytes to the site of infection. In turn, bacterial
human pathogens have evolved different strategies to
specifically impair the complement response. Here, we
review the large arsenal of complement inhibitors produced
by the gram-positive pathogens Staphylococcus aureus and
Group A Streptococcus. We discuss how these bacterial
molecules provide us with new tools to treat both infectious
and inflammatory disease conditions in humans.
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Innateimmunity
The innate immune system plays a critical role in our host
defense against invading pathogens. This system consists of
three different parts: (a) the complement system, (b)
phagocytes, and (c) antimicrobial peptides. The three major
functions of the complement cascade in innate immunity
are (1) to label pathogens or immunogenic particles with
C3b and iC3b to facilitate phagocytic uptake via comple-
ment receptors, (2) to attract phagocytes by producing
chemoattractant C5a, and (3) to directly lyse gram-negative
bacteria through membrane attack complex (MAC; C5b-9)
formation (Fig. 1)[ 1]. Complement is initiated by two
specific recognition pathways, the classical and lectin
pathway, which are amplified by the alternative pathway.
All three pathways converge at the formation of the C3
convertases. These bimolecular surface-bound enzyme
complexes catalyze the key reaction in complement
activation: cleavage of complement protein C3 into C3a, a
chemoattractant with bactericidal activity [2–4], and C3b
[5]. Convertase formation is pivotal in complement activa-
tion since C3b and its inactive derivative iC3b facilitate
phagocytosis. Furthermore, the deposited C3b can form
new convertases, thereby amplifying the opsonization
process. Subsequently, the high concentrations of locally
deposited C3b induce a shift in substrate specificity of the
convertase to complement protein C5. The cleavage
products of C5 are C5a, a potent chemoattractant, and
C5b that initiates the lytic pathway. Due to the resulting
C5a gradient, neutrophils migrate toward the site of
infection and phagocytose the invaders. Neutrophils kill
ingested particles intracellularly by the production of
reactive oxygen species and the release of granule con-
stituents such as proteolytic enzymes and antimicrobial
peptides. These peptides are also released into the extra-
cellular space to kill microorganisms extracellularly [6].
Together, these complement-mediated events are responsi-
ble for the efficient elimination of invading bacteria.
It has become increasingly evident that pathogens have
developed various ways to evade the constant attack of the
complement system. Pathogens produce proteins that
modulate all stages of the complement cascade. These
proteins inhibit complement recognition and amplification,
cleave complement proteins, or interfere with complement
receptor interactions on phagocytes. A number of reviews
have been published on these specific topics [7–9]. In this
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DOI 10.1007/s00109-009-0572-ypaper, we give a broad overview of the complement
evasion strategies of the two most important gram-positive
human pathogens Staphylococcus aureus and group A
Streptococcus (GAS), and we discuss the potential of these
bacterial complement modulators as therapeutic agents.
Modulation of complement recognition and activation
The classical and lectin pathways of complement ensure
immediate recognition of invading bacteria as nonself. The
C1-complex (classical pathway) recognizes bacterium-
bound IgG and IgM while mannose-binding lectins and
ficolins (lectin pathway) bind bacterial sugar moieties. S.
aureus expresses two surface-anchored proteins that impair
IgG function (Fig. 2a): staphylococcal protein A (SpA) and
staphylococcal immunoglobulin-binding protein (Sbi). SpA
is a surface protein with four or five immunoglobulin-
binding repeat domains. Each domain can bind the Fc-part
of IgG, thereby blocking the interaction with Fc receptors
on neutrophils in vitro [10, 11]. Sbi consists of four small
domains, of which two (Sbi-I and Sbi-II) can bind IgG [12].
Next to blocking Fc-receptor-mediated phagocytosis, Sbi
has been suggested to block binding of C1q and subsequent
activation of the classical pathway.
Another strategy to prevent recognition is to eliminate
opsonic molecules from the bacterial surface by proteolytic
degradation. Staphylokinase (SAK) is a secreted protein
that binds and activates surface-bound plasminogen into
plasmin, which may enhance bacterial invasion through
host tissues. Interestingly, it has been shown that SAK is
anti-opsonic as well. SAK-mediated plasmin deposition on
the bacterial surface can cleave IgG and C3b and thereby
inhibit phagocytosis in vitro [13]. GAS expresses several
proteases that directly cleave IgG: the Endoglycosidase in
Streptococcus pyogenes (EndoS) specifically hydrolyzes
the asparagine-linked glycan in the CH2 domain of IgG; the
IgG-degrading enzyme of S. pyogenes (IdeS or Mac-1),
Mac-2, and streptococcal pyrogenic exotoxin B (SpeB) all
cleave IgG in the hinge region [14, 15].
Modulation of complement amplification
Formation of the C3 convertases is elemental for amplifi-
cation of complement activation and downstream immune
Fig. 1 Schematic overview of the complement system. The comple-
ment cascade is activated by recognition of microbe-bound antibodies
or microbial sugars by the C1 complex (CP) or the MBL- and ficolin-
MASP-2 complex (LP), respectively. Both C1s and MASP-2 cleave
complement proteins C4 and C2 to generate the CP/LP C3 convertase:
C4b2a. The Alternative Pathway (AP) C3 convertase C3bBb is
generated after binding of fB to surface-bound C3b and subsequent
cleavage by fD. The AP C3 convertase is stabilized by the positive
regulator human properdin [47, 48]. Both C3 convertases (C4b2a and
C3bBb) cleave C3 into C3a and C3b. C3b covalently binds to
bacterial surfaces, thereby amplifying complement activation through
formation of new C3 convertases and contributes to phagocytosis,
antigen presentation, and formation of C5 convertases (C4b2a3b and
C3bBb3b). C5 convertases cleave C5 into the anaphylatoxin C5a,
which attracts neutrophils to the site of infection, and C5b, which
forms a complex with complement proteins C6–C9 to generate the
membrane attack complex
116 J Mol Med (2010) 88:115–120responses. There are three ways by which S. aureus and
GAS modulate this central step in the complement cascade
(Fig. 2b):
1. Cleavage of C3
The abundant GAS protease SpeB is, next to cleaving IgG,
involved in breakdown of C3. Comparison of wild-type GAS
and a SpeB knockout showed that SpeB blocks neutrophil
recruitment to the site of infection and subsequent phagocy-
tosis and bacterial clearance in vivo [16, 17]. The S. aureus
surface protein clumping factor A (ClfA) can bind the human
C3b protease factor I (fI), thereby enhancing cleavage of
surface-bound C3b into iC3b in vitro [18].
2. Direct inactivation of C3 convertases
Convertases are the major complement target among S.
aureus immune evasion strategies. S. aureus secretes five
different molecules that directly inhibit these central
enzyme complexes. Staphylococcal complement inhibitor
(SCIN) and its homologues SCIN-B and SCIN-C are highly
effective C3 convertase inhibitors that block conversion of
C3 and subsequent phagocytosis and C5a formation in vitro
at low concentrations [19]. The alternative pathway C3
convertase consists of a cofactor (C3b) which is loosely
bound to the protease subunit (Bb). Recent structural
studies revealed that the small 10-kD SCIN protein fixates
the convertase conformation and as such hampers a critical
rearrangement of the protease subunit Bb in relation to
substrate C3 [20, 21]. The action of SCIN on the classical
pathway convertase remains to be resolved but seems to be
caused by a stabilizing mechanism as well [19]. Extracel-
lular fibrinogen-binding protein (Efb) and extracellular
complement-binding protein (Ecb) can modulate the alter-
native pathway convertase by binding to the C3b molecule
directly [22]. The crystal structures of both molecules in
complex with the C3d domain of C3 have revealed their
exact binding sites [23, 24]. Interestingly, since the C3d
fragment of C3 is involved in stimulation of adaptive
immune responses, it was recently suggested that Efb
functions as an adaptive immunity modulator as well [25].
3. Binding or cleavage of human convertase regulators
To protect host tissues from excessive complement
activity, humans express complement regulators that down-
regulate convertase activity. A large number of pathogens
express molecules that attract these regulators to their
surface. The staphylococcal IgG-binding molecule Sbi has a
diverse role in complement modulation. Next to its two IgG-
binding domains, Sbi-III and IV, it can also bind to C3 [26].
Furthermore, Sbi binds the human complement regulators
factor H (FH) and factor H-related proteins and can form a
stable tripartite complex with C3 and FH [27]. Altogether,
these actions result in inhibition of the alternative pathway in
vitro. The streptococcal M protein is a multifunctional
surface molecule that binds four different human convertase
regulators: FH, factor H like-1 (FHL1), membrane cofactor
protein (CD46), and C4-binding protein (C4BP). M protein
consists of two polypeptide chains configured in an alpha-
helical coiled coil complex that is anchored to the cell
membrane via its C terminus [28–30]. From the N to the C
Fig. 2 Bacterial evasion of complement recognition (a) and opsoni-
zation (b). Illustrated are proteins of S. aureus (red) and GAS (yellow)
that modulate complement recognition and opsonization. a To prevent
recognition by the classical pathway, S. aureus expresses the surface
proteins ProtA and Sbi. Both proteins bind the Fc tail of IgG
preventing its interaction with FcR on neutrophils. Another mecha-
nism to prevent recognition is by inactivating IgG, either directly by
proteases IdeS, Mac-2, and SpeB, or indirectly by SAK-activated
plasmin. b There are three ways by which S. aureus and GAS
modulate opsonization: (1) C3 cleavage; directly by SpeB or indirectly
by SAK-mediated activated plasmin. ClfA binds human fI, thereby
enhancing C3 cleavage. (2) Convertase modulation; S. aureus
inactivates the C3 convertases by secreting SCIN, SCIN-B, SCIN-C,
Efb, and Ecb. (3) Modulating host regulators; Sbi and the streptococ-
cal M-protein bind the negative convertase regulators (human FH,
FHL1, C4BP, and CD46) while SpeB cleaves the positive convertase
regulator, properdin
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variable (a), variable (b), and conserved (c and d). Depend-
ing on the M type, the hypervariable region can bind FH,
FHL-1 [31], and C4BP [32]. By binding these complement
regulators, M protein limits deposition of C4b and C3b
increasing GAS resistance to phagocytosis [33]. In vivo
studies with strains expressing mutated M protein indicate
that protein is an important GAS virulent factor [34]. Finally,
SpeB also digests the positive convertase regulator proper-
din, making the streptococci more resistant to neutrophil
killing in vitro [35].
Modulation of the complement effector functions:
inhibiting C5 activation and neutrophil migration
In the final step of the complement cascade, the C5 convertases
cleave C5 to generate the important chemoattractant C5a that
directs neutrophils to the site of infection. S. aureus and GAS
use various approaches to evade the C5a-mediated immune
responses (Fig. 3). Staphylococcal superantigen-like 7 (SSL7)
is a secreted protein that specifically binds to C5 [36]a n d
thereby prevents C5 activation into C5b and C5a in vitro (J.
Bestebroer, personal communication). Efb and Ecb are very
potent inhibitors of C5a responses in vitro and in vivo [22].
These molecules elicit their immune modulating capacity by
binding the C3b part of the C5 convertase complex. GAS uses
the cell-associated peptidase ScpA to directly target C5a.
ScpA cleaves C5a and blocks chemotaxis of phagocytes
toward the site of infection [37]. In a mouse pneumonia
model, it was shown that the ScpA knockout mutant was less
virulent than wild-type GAS [38]. Modulation of C5a
responses by S. aureus proceeds through inhibition of the
C5a receptor (C5aR). The chemotaxis inhibitory protein of
S. aureus (CHIPS) is a 14-kD excreted protein that effectively
blocks neutrophil recruitment toward C5a in vitro by binding
the C5aR with high (nanomolar) affinity [39]. The recent
nuclear magnetic resonance (NMR) structure of CHIPS in
complex with the N terminus of the C5aR showed two
sulfated tyrosine (residues 11 and 14) of the C5aR to be
essential for the interaction in between the C5aR and the
inhibitor CHIPS [40].
Cleavage of C5 also results in formation of C5b, the
molecule that initiates the formation of the membrane attack
complex (C5b-9). This complex can damage target cells such
as gram-negative bacteria. MAC formation isoften monitored
in vitro by a so-called hemolytic assay in which erythrocytes
(often sheep or rabbit) are used as a direct target for
complement activation and hemolysis. The S. aureus proteins
SCIN, Efb, Ecb, and SSL7 block MAC-mediated erythrocyte
hemolysis since they inhibit the complement cascade
upstream of MAC formation. The highly variable strepto-
coccal inhibitor of complement (SIC) from GAS was found
to specifically block formation of the MAC by binding to the
C5b-7 complex and preventing erythrocyte hemolysis in
vitro [41]. The relevance of MAC inhibition by gram-
positive bacteria remains unclear since they are naturally
protected from lysis via their thick cell wall. The SIC
molecule also interacts with several human antimicrobial
peptides (LL-37, defensins) [42], and this might be more
relevant for protecting GAS from host immunity.
Complement evasion molecules as tools and targets
in therapy
Bacterial complement modulators have important applica-
tions for the treatment of inflammatory diseases where
complement is directed against our own cells [43]. Per
definition, molecules that counteract acute innate immune
Fig. 3 Bacterial evasion of C5-mediated responses. Illustrated are
proteins of S. aureus (red) and GAS (yellow) that modulate C5-
mediated responses. Efb and Ecb block the formation of C5
convertases and thereby inhibit C5a and MAC generation. SSL7
binds to C5 and prevents the cleavage of C5 into C5a and C5b.
Neutrophil influx and phagocytosis are inhibited by CHIPS, which
binds the C5aR, and ScpA that cleaves C5a. SIC inhibits the
formation of the MAC, the final step in the complement cascade
118 J Mol Med (2010) 88:115–120mechanisms are anti-inflammatory compounds. As opposed
to several bacterial toxins, the high specificity and the mode
of action that depends entirely on protein–protein inter-
actions makes these nontoxic proteins suitable anti-
inflammatory drugs. It is tempting to speculate that these
molecules could be used as injectables in acute inflamma-
tory disorders. However, since these molecules are derived
from common human pathogens, pre-existing antibodies
severely complicate this approach. Furthermore, a number
ofthe describedmolecules appeartobehuman-specificwhich
complicates functional studies in vivo [19, 44, 45] However,
the immunological molecules that are attacked by these
factors might prove to be the essential targets to tackle in
anti-inflammatory therapy. We feel that the bacterial products
could be used as an indicator of the “Achilles heel” of the
human immune system—almost at the atomic level. Espe-
cially, since the 3-D structures of a number of molecules in
context with their target are now elucidated in several
crystallographic and NMR studies [19, 20, 25, 40, 46], this
opens new possibilities for smart design of small-molecule
therapeutics. Thus, we can copy these evolutionary-designed
molecules to counteract the detrimental effects of comple-
ment activation in inflammatory disease states.
Next to their potential as anti-inflammatory compounds,
we believe that targeting of complement evasion molecules
should be included in future strategies to fight bacterial
infections. The evasion molecules described above not only
suppress natural immunity during an infection but also
hamper the current attempts to create effective vaccines.
The efficacy of vaccines is held back by the existing
bacterial immune evasion strategies since they prevent
neutrophils or complement to reach the site of infection.
Even with sufficient opsonic or bactericidal antibodies on
the bacterium, nothing will happen if the innate immune
effectors are absent. Since immune evasion molecules are
essentially vaccine evasion molecules, we propose that
these molecules should be specifically targeted in the
vaccine. Alternatively, we could think of ways to neutralize
these molecules and use that in novel strategies to fight
infectious diseases. In fact, we propose to inhibit the
inhibitor and thereby decrease the advantage of the
bacterium over the host.
So, taken together, the smart attack of the bacteria on our
complement system might hold clues for future drugs in both
inflammatory as well as infectious diseases. In this way, we
could turn this powerful escape mechanism into our own
advantage.
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